Table 1.
Data given as mean ± SD or n (%).* Significant value. BMI (body mass index). CABG (coronary artery bypass grafting). CRP (C-reactive protein). INR (international normalized ratio). PCI (percutaneous coronary intervention).
| Clinical Baseline Characteristics | |||
|---|---|---|---|
| H2O2-group (n = 429) | Control-group (n = 858) | p-Value | |
| Age [years] | 69 ± 12 | 69 ± 12 | case-control matching characteristics |
| Sex [male] | 289 (67.4%) | 578 (67.4%) | |
| BMI [kg/m2] | 28 ± 4.0 | 28 ± 4.0 | |
| Procedure Time [min] | 45 ± 23 | 45 ± 23 | |
| Medical History | |||
| Dilative Cardiomyopathy | 100 (23.3%) | 182 (21.2%) | 0.39 |
| Coronary Heart Disease | 233 (54.3%) | 448 (52.2%) | 0.51 |
| Prior CABG | 96 (22.4%) | 180 (21.0%) | 0.72 |
| Prior PCI | 176 (41.0%) | 339 (33.5%) | 0.63 |
| Hypertension | 357 (83.2%) | 736 (85.7%) | 0.25 |
| Diabetes | 172 (40.1%) | 324 (37.8%) | 0.43 |
| Chronic Kidney Disease | 126 (29.4%) | 271 (31.6%) | 0.44 |
| Echocardiographic Findings | |||
| Ejection Fraction [%] | 40 ± 15 | 43 ± 16 | 0.90 |
| Current Medication | |||
| Single-Platelet-Inhibition | 117 (27.3%) | 274 (31.9%) | 0.09 |
| Dual-Platelet-Inhibition | 108 (25.2%) | 170 (19.8%) | 0.03* |
| Anticoagulation | 166 (38.7%) | 300 (34.9%) | 0.20 |
| Laboratory Values | |||
| CRP [mg/l] | 12.9 ± 24.1 | 12.4 ± 22.4 | 0.98 |
| Leucocytes [×10³/μl] | 8.0 ± 2.5 | 7.9 ± 2.9 | 0.98 |
| Platelets [×10³/μl] | 216 ± 79 | 216 ± 100 | 1.00 |
| INR | 1.3 ± 0.49 | 1.3 ± 0.44 | 1.00 |